Context Therapeutics Inc. Common Stock

CNTXNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
1.75 USD
↘ 0.28 (13.79%)AT CLOSE (11:59 AM EDT)
1.85
↗ 0.10 (5.71%)
POST MARKET (AS OF 07:43 PM EDT)
Post Market
AS OF 07:43 PM EDT
1.85
↗ 0.10 (5.71%)
🔴Market: CLOSED
Open?$2.00
High?$2.06
Low?$1.73
Prev. Close?$2.03
Volume?821.7K
Avg. Volume?778.7K
VWAP?$1.85
Rel. Volume?1.06x
Bid / Ask
Bid?$1.78 × 100
Ask?$1.96 × 400
Spread?$0.18
Midpoint?$1.87
Valuation & Ratios
Market Cap?160.8M
Shares Out?91.9M
Float?67.5M
Float %?73.5%
P/E Ratio?N/A
P/B Ratio?3.08
EPS?-$0.44
Dividend?0.00%
Ex-Dividend?N/A

CNTX is currently priced at $1.75. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place CNTX at a fair price relative to peers.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
15
Market Cap
160.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.contexttherapeutics.com
Listed
2021-10-20
Address
2001 MARKET STREET
PHILADELPHIA, PA 19103
Phone: 267-225-7416
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
64
Piotroski F-Score?0/9Weak
Altman Z-Score?9.79Safe
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.36%Low
Short Interest?920.2K
Days to Cover?1.8
Free Float67.5M
Avg Daily Volume514.9K
Settlement Date2026-05-15
Financial Health
Current Ratio?8.96Strong
Quick Ratio?8.96Strong
Cash Ratio?8.34Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
55
3.08FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-77.1%WEAK▾
ROA?
S&P
3
-68.3%WEAK▾
Cash Flow & Enterprise
FCF?$-32823631
Enterprise Value?$106.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist